Fly News Breaks for October 8, 2019
Oct 8, 2019 | 09:18 EDT
Lake Street analyst Eric Martinuzzi keeps a Buy rating on OptimizeRx with a $20 price target after the company signed a three-year exclusive agreement with NewCrop to offer digital messaging and to create a life sciences innovation lab. B negotiating an exclusive arrangement, Optimize has "outmaneuvered pharma messaging competitors," Martinuzzi tells investors in a research note. In addition, the arrangement offers potential upside to 2020 revenue forecasts, contends the analyst.
News For OPRX From the Last 2 Days
There are no results for your query OPRX